EZH2 and neoplasm: For example, in chemotherapy-resistant GBM, De La Rosa et al. found that 3-deazaneplanocin A (an EZH2 inhibitor) combined with panobinostat (an HDAC inhibitor) reduces tumor resistance and increases cell apoptosis.